RxDoctor Payments Data

Emanuel Singleton

Primary Care · Cleveland, OHNPI 1326357849

Payments from drug & device makers

$787in general payments, 2019–2025

Across 10 payments — averaging $78.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$133
  • AbbVie$125
  • Axsome Therapeutics, Inc.$125
  • Madrigal Pharmaceuticals$120
  • Ferring Pharmaceuticals Inc.$105
  • Sanofi$101
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$787 in reported general payments places this provider in the 65th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$6,787
Medicare patients
31
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide147$220,826
TrulicityDulaglutide162$193,457
JardianceEmpagliflozin105$135,748
JanuviaSitagliptin Phosphate88$107,351
RybelsusSemaglutide34$69,763
EliquisApixaban53$55,006
EntrestoSacubitril/Valsartan41$50,101
LinzessLinaclotide42$43,867
XareltoRivaroxaban36$38,183
SymbicortBudesonide/Formoterol Fumarate100$37,317
FarxigaDapagliflozin Propanediol30$32,899
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$28,373
Breo ElliptaFluticasone/Vilanterol41$25,782
Spiriva RespimatTiotropium Bromide35$19,799
MounjaroTirzepatide17$19,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort, Farxiga, Breztri Aerosphere$133$98,588156 claims
AbbVieLinzess, Creon$125$48,56057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 321 primary care providers in Ohio.

Other primary care in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →